trial

Optimizing Cognitive Remediation Outcomes in Schizophrenia

NCTId NCT02105779
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 172 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
172 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-12
Primary completion
2016-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Targeted cognitive trainingsocial cognitive training

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Sophia Vinogradov, MDPrincipal Investigator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
172
Phase
NA
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
Targeted cognitive training
drug
social cognitive training
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Psychosis
indication
Schizophrenia
indication
investigator
Sophia Vinogradov, MD
person